BioNexus Gene Lab (BGLC) stock rocketed higher on Wednesday after the chemical raw material products company announced an agreement with Fidelion Diagnostics. This agreement will have BioNexus Gene Lab acquire a strategic equity stake in Fidelion and secure exclusive rights to its VitaGuard minimal-residual-disease (MRD) platform in Southeast Asia.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
BioNexus Gene Lab and Fidelion Diagnostics have called this agreement a “DeepSeek-class leap” for liquid biopsy cancer monitoring and artificial intelligence (AI)-driven biotechnology. Also included in the agreement is an equity investment from BioNexus Gene Lab in Fidelion Diagnostics and a license fee.
Sam Tan, CEO of BioNexus Gene Lab, said, “This alliance is nothing short of a paradigm shift – the moment precision oncology gets its own ‘DeepSeek-class’ technology upgrade. By combining VitaGuard™ with our commercial network, we will deliver next-generation cancer care to 680 million people across Southeast Asia.”
BioNexus Gene Lab Stock Movement
BioNexus Gene Lab stock was up 82.96% in pre-market trading on Wednesday, following a 1.98% drop yesterday. The shares were up 59.29% year-to-date but have fallen 8.55% over the past 12 months. Today’s movement came with heavy trading, as some 27 million shares changed hands, compared to a three-month daily average of about 2.13 million units.
